Načítá se...
Valproate augments Niraparib killing of tumor cells
PARP1 inhibitors are approved therapeutic agents in ovarian carcinomas, and have clinical activity in some breast cancers. As a single agent, niraparib killed ovarian and mammary tumor cells via an ATM-AMPK-ULK1 pathway which resulted in mTOR inactivation and the formation of autophagosomes, tempora...
Uloženo v:
| Vydáno v: | Cancer Biol Ther |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Taylor & Francis
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6154859/ https://ncbi.nlm.nih.gov/pubmed/29923797 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2018.1472190 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|